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The  role  of  NK1  receptors  of the  amygdala  of rats  was investigated  in the EPM.
Injection  of  SP  or Sar  into  the  CeA  or MeA,  but  not  the  BLA,  evoked  anxiogenic-like  effects.
Anxiogenic-like  effects  of  the  SP in  the  CeA  or MeA  are  mediated  by  NK1  receptors.
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The  amygdala,  together  with  the  dorsal  periaqueductal  gray  (dPAG),  medial  hypothalamus,  and  deep
layers  of the  superior  and  inferior  colliculi,  constitutes  the  encephalic  aversion  system,  which  has  been
considered  the  main  neural  substrate  for the  organization  of  fear  and  anxiety.  The basolateral  nucleus  of
the  amygdala  (BLA)  acts  as  a ﬁlter  for aversive  stimuli  to higher  structures  while  the  central  (CeA)  and  the
medial  (MeA)  nuclei  constitute  the  output  for the  autonomic  and somatic  components  of  the  emotional
reaction  through  major  projections  to the  limbic  and  brainstem  regions.  Although  some  ﬁndings  point  to
the distinct  participation  of  the  substance  P (SP)  and  the  NK1  receptors  system  in the different  nuclei  of
the  amygdala  on the  expression  of emotional  behaviors,  it is not  clear  if  this  system  modulates  anxiety-
like  responses  in  the distinct  nuclei  of the  amygdala  as  well  as  the  dPAG.  Thus,  it  was  investigated  if  the
injection  of SP into  the  BLA,  CeA,  or MeA  affects  the expression  of  anxiety-like  responses  of  rats  submitted
to  the  elevated  plus-maze  (EPM)  test  and, if  the  effects  are  mediated  by NK1  receptors.  The  results  showed
that  SP and Sar-Met-SP  (NK1  receptor  selective  agonist)  injected  into  the  CeA  and  MeA,  but  not into  the
BLA,  caused  anxiogenic-like  effects  in the  EPM.  Altogether,  the  data  indicates  that  the  SP  may  mimic  the
effects  of  anxiogenic  stimuli  via  NK1  receptor  activation  only  in  the CeA  and  MeA  (amygdala’s  nuclei
output)  and  may  activate  the neural  mechanisms  involved  in  the  defensive  reaction  genesis.  The  SP/NK1
receptors  system  activation  may  be  phasically  involved  in very  speciﬁc  aspects  of anxiety  behaviors.
©  2014  Elsevier  Ireland  Ltd.  All  rights  reserved.Abbreviations: BLA, basolateral nucleus of the amygdala; CeA, central nucleus
f  the amygdala; dPAG, dorsal periaqueductal gray; EPM, elevated plus maze; MeA,
edial nucleus of the amygdala; NK, neurokinin receptors; PAG, periaqueductal
ray; Sal, saline; Sar, Sar-Met-SP; SP, substance P.
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The organization of fear and anxiety-like behaviors has been
related to an encephalic aversion system composed of the amyg-
dala, medial hypothalamus, dorsal periaqueductal gray (dPAG),
and deep layers of the superior and inferior colliculi [4,16]. Several
reports point to the amygdaloid complex as an important func-
tional link in the neurocircuitry responsible for the integration of
aversive states in the central nervous system [21,22]. Indeed, it
has been shown that the amygdala processes the stimulus input
from the environment and, depending on the type of the threat,
engages with the neural substrate of fear in the dPAG [15,18,21,38]
to which it sends direct projections [7,26]. The mechanisms
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Fig. 1. (A) Representative photomicrographs of microinjections into the central (A), medial (B) and basolateral (C) nuclei of the amygdala and outline of the injection sites on
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iross-sections from Paxinos and Watson [27]. The distance from the interaural line
he  number of injected rats because of several overlaps. Scale bars represent 500 
mygdala and BLA: basolateral nucleus of the amygdala.
nderlying modulation of anxiety-like responses depend on which
mygdaloid nucleus is activated [2,11]. The basolateral amygdala
BLA) is predominantly involved in the ﬁltering of aversive stimuli
hile the central (CeA) as well as the medial nucleus (MeA) consti-
ute the output for the autonomic and somatic components of the
efensive reaction via major projections to the hypothalamus and
rainstem regions [5,32]. The excitability of these output neurons
s regulated by a tonic inhibitory inﬂuence from the BLA [24].
Substance P (SP) is a neurokinin that is widely distributed in the
rain and has been shown to modulate stress and anxiety-linked
ehaviors [13,14,20]. A large number of peptidergic neurons in the
mygdala, including the neurokininergic neurons, project to the
AG [17] where microinjection of SP elicits defensive behaviors
9,10]. Three NK receptors have been identiﬁed so far: NK-1, NK-
, and NK-3. Despite the fact that SP binds to all receptor types,
t shows much higher afﬁnity for NK-1 receptors [8,29], which are
eterogeneously distributed in the amygdaloid complex [30,31,35].
ctivation of SP/NK1 receptors in the different amygdaloid nuclei
as been shown to modulate the expression of learned and innate
efensive responses of rats [3,6,36,38]. SP injected into the CeA or
eA, but not in the BLA, also produced anxiogenic-like effects in
he elevated plus-maze (EPM), an effect that was blocked in the
resence of a NK1 antagonist [6,12]. We  have now extended these
ndings by investigating the effect of activating NK1 receptors
sing the highly selective NK1 agonist Sar-Met-SP and compared
ts effectiveness in different amygdaloid nuclei [23].icated below each section. The number of sites indicated in the ﬁgures is less than
ll photographs. CeA: central nucleus of the amygdala, MeA: medial nucleus of the
2. Materials and methods
Male Wistar rats weighing 150–180 g were obtained from
the breeding facility of the University of São Paulo at Ribeirão
Preto. Animals were housed in a temperature-controlled (22 ± 1 ◦C)
room and maintained on a 12 h light/12 h dark cycle with lights
on at 7:00 a.m. Rats were housed in groups of ﬁve per cage
(40 cm × 33 cm × 18 cm)  and given free access to food and water.
The experiments were performed in accordance with the Brazilian
Society of Neuroscience and Behavior Guidelines for the Care and
Use of Laboratory Animals. The procedures were approved by the
Committee on Animal Research and Ethics (CEUA) of the University
of Sao Paulo (No. 09.1.84.54.7).
The animals were anesthetized with tribromoethanol
(250 mg/kg, i.p.) and placed in a stereotaxic frame (David Kopf,
Tujunga, CA, USA) with the upper incisor bar at 3.3 mm below the
interaural line. A unilateral stainless steel guide cannula (12 mm,
24 gauge) aimed at the right BLA, CeA or MeA  was implanted
in each animal. With the interaural line as the reference point
for each plane, the following coordinates were used: for BLA –
antero-posterior (AP) 6.1 mm,  medio-lateral (ML) 4.7 mm,  and
dorso-ventral (DV) 5.3 mm;  for CeA – AP 6.1 mm,  ML  4.2 mm,  and
DV 4.9 mm and for MeA  – AP 6.2 mm,  ML  3.2 mm,  and DV 6.0 mm
[27].
Experiments began 5 days after guide cannula implantations.
The rats were subjected to the EPM test as described in detail
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Fig. 2. Effects of SP (35 pmol/0.2 L) or Sat-Met-SP (Sar, 50 pmol/0.2 L) injected
into the basolateral (BLA), central (CeA), or medial (MeA) nuclei of the amygdala on
rat  behavior in the elevated plus maze. Each bar represents mean + SEM of frequency
of  entries in the open and closed arms (A and B, respectively) and % of time spent
in  the open arms compared with total entries (C). *p < 0.05 compared with controlG.S. Bassi et al. / Neuroscie
n previous studies [6,28]. Brieﬂy, the rats received intra-BLA, -
eA, or -MeA microinjections of SP (35 pmol/0.2 l; Sigma-USA) or
he NK-1 agonist Sar-Met-SP (Sar; 50 and 100 pmol/0.2 l; Sigma-
SA). Both drugs were dissolved in saline (Sal) and the doses used
ere selected based on previous publications from our laboratory
1,10]. In order to minimize the spread of the volume of the injec-
ions, we used a glass micropipette for microinjections, according
o a technique described elsewhere [25,33]. In brief, micropipettes
ere made of a fused silica capillary (o.d. 150 m,  i.d. 75 m;
luzeau Info Lab, France). To prevent cannula breaks, the capil-
ary was ﬁxed in a device made with needles of 0.60 × 25 mm and
.00 × 25 mm (Becton–Dickinson). The fused silica capillary pro-
ruded 3.0 mm beyond the guide-cannula to reach the BLA, CeA or
eA. The micropipette was linked to a 5 l Hamilton syringe by
eans of polyethylene tubing (PE-10; Becton–Dickinson, Franklin
akes, NJ) connected to a microinfusion apparatus (Harvard, USA).
 volume of 0.2 l was injected over 60 s. Following the end of the
njections, the microinjection pipettes were held inside the brain
or a further 60 s to maximize diffusion of the drug away from the
ip. Immediately after SP or 5 min  after the Sar-Met-SP microin-
ections, the rat was gently placed in the central area of the EPM
ith the nose facing one of the closed arms and its behavior was
bserved for 5 min. The exploratory behavior (conventional EPM
easures, i.e., number of entries and time spent in the arms) was
ecorded by a video camera interfaced with a monitor and a VCR in
n adjacent room for later analysis (Noldus software, Amsterdam,
he Netherlands). The luminosity at the level of the open arms of
he EPM was 20 lx.
Upon completion of the experiments, the animals were deeply
nesthetized with urethane and perfused intracardially with 0.9%
al followed by 10% formalin solution. Three hours later, the brains
ere immersed in 30% sucrose. Seven days later, the brains were
rozen and serial brain sections (60 m)  were cut using a cryostat
Leica, Wetzlar, Germany), thaw-mounted on gelatinized slides and
tained with cresyl violet in order to localize the sites of injection
ith reference to Paxinos and Watson [27].
. Results
Data are expressed as mean + SEM. One-way analysis of vari-
nce (ANOVA) was used to assess the effects of SP and Sar-Met-SP
icroinjections into the BLA, CeA or MeA. Fisher’s least signiﬁcant
ifference post hoc comparisons were performed when signiﬁcant
verall F-values were obtained in the ANOVA (p < 0.05).
Photomicrographs of representative microinjections sites and
he location of the cannula tips and in the BLA, CeA, or MeA  are
hown in Fig. 1A–C. Following injection of Sar-Met-SP into CeA and
eA, one-way ANOVA showed signiﬁcant differences in the fre-
uency of entries in the open arms (F3,29 = 11.32 and F3,35 = 14.28,
espectively; p < 0.05 in all cases) and in the percentages of time
pent in the open arms/total (F3,29 = 6.13 and F3,35 = 93.60, respec-
ively; p < 0.05 in all cases). Post hoc comparisons revealed that
njections of both SP and Sar-Met-SP into the CeA and MeA  reduced
he frequency of entries in the open arms as well as the percentages
f time spent in these arms/total in relation to the control group
Fig. 2A and C, respectively). There was no signiﬁcant differences
n the frequency of closed arm entries: F3,29 = 0.23; p > 0.05 for
he CeA and F3,35 = 1.44; p > 0.05 for the MeA  (Fig. 2B). In contrast,
he statistical analysis showed no signiﬁcant differences in the
easures evaluated in the EPM test (frequency of entries in the
pen and closed arms (F3,31 = 0.39 and 0.46; p > 0.05, respectively)
nd in the percentages of time spent in the open arms/total
F3,31 = 0.45; p > 0.05) (Fig. 2A–C) after microinjections of SP or
ar-Met-SP into the BLA. Due to the similarity of the effects of both
oses of Sar-Met-SP on the behavior of rats in the EPM, we chose
o illustrate only the effects of the dose of 50 pmol in Fig. 2A–C.(Sal).  BLA (Sal: n = 7; SP: n = 10; Sar: n = 8), CeA (Sal: n = 9; SP: n = 10; Sar: n = 7), and
MeA  (Sal: n = 11; SP: n = 9; Sar: n = 11).
4. Discussion
The present study showed that SP injected into the CeA or
MeA, but not into the BLA, caused anxiogenic-like effects in the
EPM, in agreement with previous ﬁndings [6,12] suggesting that SP
produces defensive behaviors in this point of the encephalic aver-
sion system as well as in the dPAG and hypothalamus [6,9,10,12,34].
These effects of SP were reproduced by microinjection of Sar-Met-
SP, a neurokinin agonist with high selectivity for the NK1 receptor
in brain tissue [23]. Thus, NK1 receptor activation in the CeA and
also in the MeA  is able to modulate the aversiveness associated with
the open space and height that the EPM represents to the animal
[28]. These effects cannot be attributed to motor alterations since
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he treatments did not change the number of entries in the closed
rms of the EPM.
The dose of SP used in the present study was chosen based on a
ose we had found previously to be effective in the PAG [10]. It is
owever, higher than the doses that have since been reported by us
nd by others to be effective in the amygdala [6,12]. Indeed, when
njected into the amygdala bilaterally SP was effective at much
ower doses than used here [12]. Like other peptides, often produces
 dose-related effect that is commonly represented by an inverted
-shaped dose response relationship [9,12,19,35]. We  have shown
reviously that responsiveness to SP after unilateral injection
nto the amygdala is essentially constant over the dose range of
0–100 pmol [6]. Therefore, we believe that the effects of SP seen
n the present study represent a physiological action of the peptide.
owever, we cannot rule out the possibility that at the dose used
35 pmol), SP may  not be selective for the NK1 receptor subtype.
The NK1 receptor-mediated effects of Sar-Met-SP were local-
zed to the CeA and MeA. Both nuclei are the main output for the
utonomic and somatic components of the emotional reactions via
heir projections to the hypothalamus and brainstem regions [5,32].
nterestingly, in the present study the administration of SP or Sar-
et-SP into the BLA did not produce any effect on behavior in the
PM, in agreement with a previous reported [6]. In contrast, other
tudies have suggested an involvement of NK1 receptors in the BLA
n the expression of emotional responses. However, in those stud-
es the rats were submitted to a different type of stressful procedure
han the EPM [3,36,38]. Thus, the kind of aversion elicited in dif-
erent models may  be relevant. In the EPM, unlike immobilization
tress, maternal separation, and fear potentiated startle, the ani-
als have the choice to avoid the aversive environment. In other
ords, the aversive stimulus is completely avoidable depending on
he free decision of the rat. It is possible that the SP/NK1 receptor
ystem of the BLA does not participate in this type of decision-
aking process, even though this amygdaloid nucleus tonically
nhibits the excitability of the output neurons of CeA and MeA  [24]
nd is linked with the dPAG [37]. On the other hand, SP in the CeA
r MeA  may  modulate the defensive mechanisms by acting on the
K1 receptors only when they are called into play by the presence
f aversive stimuli, i.e., this mediation is phasic [6,12]. Thus, there
ay  be differential participation of the NK1 receptor system in dif-
erent amygdaloid nuclei depending on the context of a stress, i.e.,
hether some control over the environment is given to the rat on
he control of this response.
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